Health & science
Breast Tumor Diversity Tied to Metastasis Risk and Tamoxifen Timing
A new doctoral thesis from Karolinska Institutet links variation inside breast tumors and between patients to metastasis risk and how much women gain from endocrine therapy. Tamoxifen's payoff differs sharply between luminal A and luminal B, and one tumor pattern raised metastasis rates by roughly 40%.
Continue reading →Latest news
As it breaksAdneuris Files FDA Application for First Dual-NMR Pain Drug Cebranopadol
Adneuris Therapeutics has submitted an NDA to the FDA for cebranopadol, an investigational first-in-class dual-NMR agonist for moderate-to-severe acute pain in adults. Two Phase 3 trials in surgical pain models hit their primary endpoints, and abuse-potential studies showed it beat oxycodone and tramadol head-to-head. The FDA has about 60 days to decide whether to accept the filing.
Six kinds of immune cells in fat may explain why obesity differs by sex
UC Riverside scientists say fat tissue contains six distinct populations of eosinophils — immune cells usually tied to asthma and allergies — and they behave differently in male and female mice. One population protects against obesity-related inflammation in females, while males on a high-fat diet build more inflammatory versions. The team hopes the mouse work points toward sex-specific metabolic treatments.
Eli Lilly's Foundayo pill cuts sleep apnea events in late-stage trial
Eli Lilly's obesity pill Foundayo sharply reduced sleep apnea severity in two late-stage studies, the drugmaker said Monday. Lilly plans to ask the FDA to approve the daily pill for obstructive sleep apnea by year-end, chasing its own Zepbound into the market.
Brain Plots Emotions on a Hexagonal Grid, Scans Suggest
Your brain doesn't stash emotions in separate boxes — it maps them onto a hexagonal grid, according to a new PLOS Biology study. Scans of 18 adults caught the ventromedial prefrontal cortex tracking feelings along 60-degree angles, the same geometry the brain uses to navigate physical space.
Little Giant recalls 3.6 million ladders after skull fractures, brain injuries
Little Giant is pulling more than 3.6 million ladders after its Rapid Locks failed to lock, sending users to the ground. The CPSC says 39 people reported the defect, and 19 of them were hurt, including three with skull fractures and traumatic brain injuries.
Europe Clears Oncopeptides' Myeloma Drug for Earlier Third-Line Use
The European Commission widened melphalan flufenamide's label on Nov. 9, 2026, letting doctors use it after two prior myeloma therapies instead of three. Oncopeptides says dropping the triple-class refractory requirement could roughly double the eligible European population — and roughly double the treatment cycles patients receive.
HEPA Filters in the Bedroom Cut Blood Sugar Swings in Prediabetes, Trial Finds
A first-of-its-kind human trial gave people with prediabetes real air filters for their bedrooms — and their blood sugar steadied. Cleaner air slashed daily glucose swings by nearly 8% and blunted post-breakfast spikes. Researchers at NYU Langone say it's a cheap add-on to diet, exercise and medication.
FDA Probes Whether Novartis Gene Therapy Zolgensma Spurs Tumors in Kids
The FDA is investigating whether Novartis's Zolgensma, a one-time gene therapy given to babies with spinal muscular atrophy, is linked to tumor growth. Novartis disclosed Friday that two treated children developed tumors showing signs of a connection, part of nine tumor reports since 2019. Regulators still say the drug's benefits outweigh its risks.
11 states bankroll their own ACA subsidies as premiums spike 58%
At least 11 states are putting their own cash behind Obamacare premiums for 2027, picking up where lapsed federal enhanced subsidies left off. Rhode Island and Virginia are launching programs for the first time, while California widened eligibility to 200,000 more people. Premiums climbed 58% on average after Washington let the subsidies die.
Compass Pathways hands FDA its psilocybin NDA for hard-to-treat depression
Compass Pathways has finished filing its New Drug Application with the FDA for COMP360, a synthetic psilocybin pill aimed at treatment-resistant depression. CEO Kabir Nath called it the largest late-stage clinical program in psychedelic treatments, and the company says it's already built the commercial muscle to launch if approval lands.
Only 6.4% of stroke survivors get the NHS rehab they are owed
Stroke survivors across England, Wales and Northern Ireland are being short-changed on recovery. Just 6.4% get the three hours of daily therapy NICE says they should, and the Stroke Association calls the figures damning. Stroke costs the UK an estimated £25.7bn a year.
FDA Decision Week: Summit, Cytokinetics and Teva Await Verdicts
The FDA is set to rule on three drug applications this week, spanning lung cancer, heart disease and acute agitation. Summit Therapeutics' ivonescimab, Cytokinetics' Myqorzo label update and Teva's newly acquired IGALMI are all on the line, right after the agency cleared Johnson & Johnson's Rybrevant Faspro.
Singapore's Dried 'Fish Gills' Are Critically Endangered Rays, DNA Reveals
Researchers DNA-tested 439 dried gill raker samples from 21 Singapore sellers and found every identified one came from a manta or devil ray. Two Critically Endangered species made up roughly 80% of the matches, exposing a trade that hides behind a bland "fish gills" label.
Chesapeake Ospreys Starve as Menhaden Vanish From the Bay
Chesapeake Bay's ospreys just logged their worst breeding season on record, and researchers point at a collapsing food supply: Atlantic menhaden. Pairs are raising roughly 0.26 chicks each, far below the 0.8 needed to keep the population steady, according to William & Mary's Center for Conservation Biology.